A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance

被引:36
作者
Harrigan, PR
Salim, M
Stammers, DK
Wynhoven, B
Brumme, ZL
McKenna, P
Larder, B
Kemp, SD
机构
[1] BC Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada
[2] Virco United Kingdom Ltd, Cambridge, England
[3] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England
[4] Virco NV, Mechelen, Belgium
关键词
D O I
10.1128/JVI.76.13.6836-6840.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Y318F substitution in the 3' region of human immunodeficiency virus type I (HIV-1) reverse transcriptase (RT) has been linked to normucleoside RT inhibitor (NNRTI) resistance in vitro. A systematic search of a large phenotypic-genotypic database (Virco) linked the Y318F substitution with a >10-fold decrease in NNRTI susceptibility in >85% of clinically derived isolates. There was a significant association between Y318F and use of delavirdine (P = 10(-11)) and nevirapine (P = 10(-6)) but not efavirenz (P = 0.3). Site-directed HIV-1 Y318F mutants in an HXB2 background displayed 42-fold-decreased susceptibility to delavirdine but <3-fold-decreased susceptibility to nevirapine or efavirenz. Combinations of Y318F with K103N, Y181C, or both resulted in decreased efavirenz susceptibility of 43-, 3.3-, and 84-fold, respectively, as well as >100- and >60-fold decreases in delavirdine and nevirapine susceptibility, respectively. These results indicate the importance of the Y318F substitution in HIV-1 drug resistance.
引用
收藏
页码:6836 / 6840
页数:5
相关论文
共 19 条
[1]   Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy [J].
Bacheler, LT ;
Anton, ED ;
Kudish, P ;
Baker, D ;
Bunville, J ;
Krakowski, K ;
Bolling, L ;
Aujay, M ;
Wang, XV ;
Ellis, D ;
Becker, MF ;
Lasut, AL ;
George, HJ ;
Spalding, DR ;
Hollis, G ;
Abremski, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2475-2484
[2]   Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen [J].
Casado, JL ;
Hertogs, K ;
Ruiz, L ;
Dronda, F ;
Van Cauwenberge, A ;
Arnó, A ;
Garcia-Arata, I ;
Bloor, S ;
Bonjoch, A ;
Blazquez, J ;
Clotet, B ;
Larder, B .
AIDS, 2000, 14 (02) :F1-F7
[3]   Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260) [J].
Demeter, LM ;
Shafer, RW ;
Meehan, PM ;
Holden-Wiltse, J ;
Fischl, MA ;
Freimuth, WW ;
Para, MF ;
Reichman, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :794-797
[4]   A MUTATION IN REVERSE-TRANSCRIPTASE OF BIS(HETEROARYL)PIPERAZINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 THAT CONFERS INCREASED SENSITIVITY TO OTHER NONNUCLEOSIDE INHIBITORS [J].
DUEWEKE, TJ ;
PUSHKARSKAYA, T ;
POPPE, SM ;
SWANEY, SM ;
ZHAO, JQ ;
CHEN, ISY ;
STEVENSON, M ;
TARPLEY, WG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (10) :4713-4717
[5]   Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor [J].
Esnouf, RM ;
Ren, JS ;
Hopkins, AL ;
Ross, CK ;
Jones, EY ;
Stammers, DK ;
Stuart, DI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3984-3989
[6]  
Harris M, 2000, REV MED VIROL, V10, P217, DOI 10.1002/1099-1654(200007/08)10:4&lt
[7]  
217::AID-RMV279&gt
[8]  
3.0.CO
[9]  
2-L
[10]   Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type β-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. -: J Antimicrob Chemother 1998; 42:269-270 [J].
Vahaboglu, H ;
Saribas, S ;
Akbal, H ;
Ozturk, R ;
Yucel, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) :269-270